Price
CHART BY
Frequently asked questions
What is Entrada's market capitalization?
The market capitalization of Entrada is $299.70M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Entrada?
Entrada's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.998. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Entrada's stock?
Currently, 8 analysts cover Entrada's stock, with a consensus target price of $18.75. Analyst ratings provide insights into the stock's expected performance.
What is Entrada's revenue over the trailing twelve months?
Over the trailing twelve months, Entrada reported a revenue of $5.74M.
What is the EBITDA for Entrada?
Entrada's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$172.52M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Entrada?
Entrada has a free cash flow of -$131.64M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Entrada have, and what sector and industry does it belong to?
Entrada employs approximately 152 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Entrada's shares?
The free float of Entrada is 22.21M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $299.70M
- EPS (TTM)
- -$3.998
- Free Float
- 22.21M
- Revenue (TTM)
- $5.74M
- EBITDA (TTM)
- -$172.52M
- Free Cashflow (TTM)
- -$131.64M
Pricing
- 52W span
- $4.93$16.43
Analyst Ratings
The price target is $18.75 and the stock is covered by 8 analysts.
Buy
7
Hold
1
Sell
0
Information
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which provides of a class of medicines that engages in intracellular targets. Its Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The company was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.
- Employees
- 152
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- TRDA
Fundamentals & EOD data from FactSet